Complications of hyperglycaemia with PI3K–AKT–mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials
Main Authors: | Geuna, E, Roda, D, Rafii, S, Jimenez, B, Capelan, M, Rihawi, K, Montemurro, F, Yap, T A, Kaye, S B, De Bono, J S, Molife, L R, Banerji, U |
---|---|
Format: | Online |
Language: | English |
Published: |
Nature Publishing Group
2015
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4705886/ |
Similar Items
-
Targeting the PI3K-AKT-mTOR signaling network in cancer
by: Khan, Khurum H., et al.
Published: (2013) -
PI3K/Akt/mTOR inhibitors in breast cancer
by: Lee, Joycelyn JX, et al.
Published: (2015) -
PI3K/AKT/mTOR Pathway in Angiogenesis
by: Karar, Jayashree, et al.
Published: (2011) -
Targeting the PI3K/Akt/mTOR Pathway – Beyond Rapalogs
by: Markman, Ben, et al.
Published: (2010) -
Role of dual PI3/Akt and mTOR inhibition in Waldenstrom's Macroglobulinemia
by: Sacco, Antonio, et al.
Published: (2010)